{
    "clinical_study": {
        "@rank": "23584", 
        "brief_summary": {
            "textblock": "To compare the efficacy and safety of orally administered Procysteine with placebo in\n      HIV-infected patients who are receiving 1 of the following: (1) zidovudine (AZT) alone; (2)\n      didanosine (ddI) alone; (3) AZT plus ddI; or (4) AZT plus zalcitabine (ddC)."
        }, 
        "brief_title": "A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides", 
        "completion_date": "January 1994", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients must receive treatment with antiretroviral nucleosides in addition to study\n      treatment. Patients are randomized equally into 1 of 3 outpatient dosage groups. Group 1\n      receives placebo; Group 2 receives a low dose of Procysteine; and Group 3 receives a higher\n      dose of Procysteine. Patients receive study treatment for 6 months (total duration of\n      patient participation is 30 weeks)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n        Antiretroviral nucleosides (AZT alone, ddI alone, AZT plus ddI, or AZT plus ddC). Regimen\n        may be altered on or after Week 16.\n\n        Allowed:\n\n          -  Appropriate topical treatment or local radiotherapy for KS.\n\n          -  Treatment or prophylaxis for opportunistic infections, including pentamidine,\n             cotrimoxazole, acyclovir, fluconazole, etc., at the discretion of the investigator.\n\n        Patients must have:\n\n          -  Documented serologic evidence confirming HIV infection.\n\n          -  Ability to participate in an outpatient study for at least 26 weeks.\n\n          -  Either:\n\n          -  (a) diagnosis of AIDS or AIDS-Related Complex (ARC) with CD4 count of 50 - 300\n             cells/mm3, or (b) CD4 count of 50 - 200 cells/mm3 and no symptoms of AIDS\n             (asymptomatic). (Note:\n\n          -  Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 count\n             of 50 - 200 cells/mm3.)\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Evidence of organ involvement with CMV and/or positive blood cultures for\n             Mycobacterium avium.\n\n          -  Life expectancy less than 26 weeks.\n\n          -  Malignancy or advancing Kaposi's sarcoma (KS) with advancing or unstable skin lesion,\n             or known or suspected visceral disease which requires systemic cytotoxic,\n             myelosuppressive chemotherapy.\n\n          -  Stage 2 or greater AIDS-dementia complex (ADC), defined as ability to perform basic\n             activities of self-care but inability to work or maintain more demanding aspects of\n             daily life as a result of an acquired decrease in cognitive CNS-related motor\n             function characteristic of ADC.\n\n          -  Psychological or emotional problems that prevent adequate compliance with study\n             therapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Daily Vitamin C dosage greater than 1,000 mg or daily Vitamin E dosage greater than\n             100 units.\n\n          -  N-acetylcysteine, cysteine, or glutathione.\n\n          -  Any investigational drug.\n\n          -  Systemic chemotherapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of organ involvement with cytomegalovirus (CMV) and/or positive blood\n             cultures for Mycobacterium avium.\n\n          -  Intractable diarrhea, defined as greater than 4 bowel movements per day for at least\n             2 weeks.\n\n          -  History of seizures which have not been controlled with appropriate anticonvulsant\n             medications within the previous 6 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any investigational agent or biological response modifier (including interferon or\n             corticosteroids) within 1 month of study entry.\n\n          -  Use of erythropoietin (EPO), G-CSF, or GM-CSF within 28 days of randomization.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Active alcohol or drug abuse.\n\n        Required:\n\n        Antiretroviral nucleosides (AZT alone, ddI alone, AZT plus ddI, or AZT plus ddC) for at\n        least 3 months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "125", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002114", 
            "org_study_id": "215A", 
            "secondary_id": "CN9202D"
        }, 
        "intervention": {
            "intervention_name": "Procysteine", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "official_title": "A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002114"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Free Radical Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1994"
    }, 
    "geocoordinates": {}
}